<DOC>
	<DOCNO>NCT00630240</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) common malignant tumor liver . Transcatheter arterial chemoembolization ( TACE ) traditional method palliative management patient HCC . Few previous study demonstrate serum level anticancer drug patient treat TACE similar treat systemic chemotherapy . The defense ability patient treat TACE may thus influence leakage anticancer drug systemic circulation . Since 80 % patient HCC also liver cirrhosis , toxicity anticancer drug hepatic transformation increase cause cirrhotic liver . The severity pancytopenia cirrhosis exacerbate effect bone marrow suppression cause anticancer drug . Patients high risk infection hemorrhage . Therefore , clinical importance prevent decrease leakage anticancer drug systemic circulation patient treat TACE . The procedure TACE perform previous study constant distribution tumor vessel evaluate detail . The possible risk factor leakage anticancer drug investigate . This project collect 60 patient HCC include 30 patient hepatitis B 30 patient hepatitis C. The blood level anticancer drug ( epirubicin , mitomycin C cisplatin ) determine within one hour third day TACE .</brief_summary>
	<brief_title>Risk Factors Leakage Anticancer Drugs Systemic Circulation Transcatheter Arterial Chemoembolization</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients hepatocellular carcinoma cause hepatitis B C treat TACE Previously treat antiviral drug hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>epirubicin</keyword>
	<keyword>mitomycin C</keyword>
	<keyword>cisplatin</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>